Can a Pre-Surgery immune boost stop liver Cancer's return?

NCT ID NCT07461675

Not yet recruiting Disease control Sponsor: University of Geneva, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving the immunotherapy drug atezolizumab before liver surgery can strengthen the body's immune response against liver cancer (hepatocellular carcinoma). About 30 patients will receive two doses before their operation. Researchers hope this approach might reduce the high rate of cancer recurrence after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (immunotherapy drug)
What this could lead to: If it works, this could point toward a way to lower the chance of liver cancer coming back after surgery.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. Immunotherapy can cause immune-related side effects, and the benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATO CELLULAR CARCINOMA (HCC) IMMUNOTHERAPY

Contacts and locations

Locations

Geneva University Hospitals

Geneva, 1205, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.